Chantix, the popular smoking cessation drug that has plagued
some users with serious side effects, is about to be at the centre of a series
of trials set to take place in the Northern District of Alabama. Over 1,200
Chantix lawsuits have been consolidated in multidistrict litigation that has not yet
begun, but both parties will begin preparing evidence from the initial
discovery pool this fall, and trials will commence from there. In multidistrict
litigation, pretrial processes are completed as one, and then cases may be sent
back to the courts from which they originated.
Plaintiffs are filing suit on behalf of themselves or a
family member who has experienced one of many severe Chantix side effects,
including suicide attempts and suicide ideation, episodes of rage, heart
problems, aggressive behavior, and heart attacks. The cases center around the
assertion that Pfizer did not adequately warn patients of the potential for
many of these serious side effects. In addition, there is concern over the way Chantix
was tested. Subjects with a history of mental illness were not included in
Chantix clinical trials, despite the fact that statistically people with a
history of mental illness or mental problems are much more likely to smoke. In
addition, people with such a history are the ones most likely to be affected by
Chantix psychological side effects.